Summary & Overview
HCPCS A2024: Resolve Matrix or Xenopatch, Per Square Centimeter
HCPCS Level II code A2024 denotes a Resolve matrix or xenopatch product billed per square centimeter as an add-on to a primary procedure. This code captures charges for a biologic or synthetic patch used to support tissue repair, wound closure, or grafting during surgical or procedural care. Nationally, coding and payment for adjunctive wound matrix products matter because they affect procedure-level costs, facility supply tracking, and reimbursement for advanced wound therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context and typical sites of service, plus an overview of payment and coding considerations for add-on product reporting. The publication summarizes common modifiers and payer practices where available and highlights benchmarking metrics and policy considerations relevant to supply-specific HCPCS reporting.
This resource is intended to help billing, clinical, and revenue cycle staff understand how HCPCS Level II code A2024 is used, where it is typically billed, and what sorts of documentation and claim structure to expect. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code A2024 describes a Resolve matrix or xenopatch, billed per square centimeter and is designated as an add-on reported separately in addition to a primary procedure. This code represents the supply or application of a biologic or synthetic wound matrix patch product used to support tissue repair and wound closure.
Service Type: Wound care product / surgical adjunct
Typical Site of Service: Operative or procedure setting, outpatient surgery centers, hospital outpatient departments, and wound care clinics
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a full-thickness or complex partial-thickness skin defect following trauma, excision of a non-healing wound, or surgical debridement of an infected graft site. In the operating room or procedure suite, the surgeon prepares the wound bed with debridement and hemostasis, measures the defect in square centimeters, and applies a biologic matrix or xenopatch product (bovine or porcine-derived) as an adjunctive dressing or scaffold to support tissue regeneration. The product billed with A2024 is used in addition to the primary procedure (for example, skin grafting or wound debridement) and is reported per square centimeter as an add-on supply code. Typical workflow steps: wound assessment and measurement, operative debridement, selection and sizing of the resolve matrix/xenopatch, fixation or securement to the wound bed, dressing application, and post-procedure wound care instructions. Usual sites of service include outpatient surgery centers, hospital outpatient departments, and inpatient operating rooms. Common clinical teams include general surgery, plastic surgery, vascular surgery, podiatry, and wound care specialists managing chronic or acute complex wounds.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier / default | Use when no special circumstance applies and payer requires explicit reporting. |